Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 560-567

  Moleti, Maria Luisa ^a   Al Hadad, Salma Abbas ^b   Al Jadiry, Mazin Faisal ^b   Al Darraji, Amir Fadhil ^b   Al Saeed, Raghad Majid ^b   De Vellis, Annalisa ^a   Piciocchi, Alfonso ^c   Uccini, Stefania ^a   Foà, Robin ^a   Testi, Anna Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAGHDAD TEACHING HOSPITAL   (Iraq)

^c Gruppo Malattie Ematologiche dell'Adulto Data Center   (Italy)

Author keywords

B cell NHL; Children; Developing countries

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE SULFATE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CYTODIAGNOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; ELECTROLYTE DISTURBANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYDRATION; HYPERURICEMIA; INFECTION; INTESTINAL BLEEDING; JAUNDICE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEVELOPING COUNTRIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLIC ACID; HUMANS; HYDROCORTISONE; IRAQ; LYMPHOMA, B-CELL; MALE; METHOTREXATE; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 79551641942     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22905     Document Type: Article

References (29)

1. Reiter A. Diagnosis and treatment of childhood non-Hodgkin lymphoma. Am Soc Hematol Educ Program Book, Hematology 2007; 285-296.
2. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphomas and B-cell (Sigh+) acute lymphoblastic leukemia with high dose fractionated cyclophosohamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986;4:1732-1739.
3. Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol 2003;15:695-711.
4. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-Cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94:3294-3306.
5. Woessmann W, Seidermann K, Reiter K, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-958.
6. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 Protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
7. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: Results of the FAB/LMB 96 international study. Br J Haematol 2008;141:840-847.
8. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-2743.
9. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007;109:2773-2780.
10. Howard SC, Marinoni M, Castillo L, et al. MISPO Consortium Writing Committee. Improving outcomes for children with cancer in low-income countries in Latin America: A report on the recent meetings of the Monza International School of Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer 2007;48:364-369.
11. Howard SC, Ortiz R, Baez LF, et al. MISPHO Consortium Writing Committee. Protocol based treatment for children with cancer in low-income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part II. Pediatr Blood Cancer 2007;48:486-490.
12. Magrath I, Naresh KN, Advani S, et al. Report of an international network of cancer treatment and research workshop on non-Hodgkin's lymphoma in developing countries. Blood Cells Mol Dis 2004;33:330-337.
13. Testi AM, Al-Hadad SA, Al-Jadiry MF, et al. Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq. Haematologica 2006;91:509-512.
14. The Non Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 1982; 2112-2135.
15. Murphy SB. Classification, staging and results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339.
16. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
17. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999;18:695-706.
18. Simon R, Lee YJ. Nonparametric confidence limits survival probabilities and median survival time. Cancer Treat Res 1982;66:37-42.
19. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: Wiley; 1989.
20. Frangoul H, Al-Jadiry MF, Shyr Y, et al. Shortage of chemotherapeutic agents in Iraq and outcome of childhood acute lymphocytic leukemia, 1990-2002. N Engl J Med 2008;359:435-437.
21. Nouel A, Acquatella G, Insausti CI, et al. Outcome of children with B cell lymphoma in Venezuela with LMB-89 protocol. Pediatr Blood Cancer 2004;43:580-586.
22. Klumb CE, Schramm MT, De Resende LM, et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil. J Pediatr Hematol Oncol 2004;26:462-468.
23. Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa-Report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 2008;50:1138-1142.
24. Hesseling PB, Broadhead R, Molyneux E, et al. Malawi pilot study of Burkitt lymphoma treatment. Med Pediatr Oncol 2003;41:532-540.
25. Al-Attar A, Pritchard J, Al-Saleem T, et al. Intensive chemotherapy for non-localised Burkitt's lymphoma. Arch Dis Child 1986;61:1013-1019.
26. Al-Attar A, Attra A, al-Bagdadi R, et al. 'Debulking' surgery is unnecessary in advanced abdominal Burkitt lymphoma in Iraq. Br J Cancer 1989;59:610-612.
27. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
28. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukaemia or lymphoma. J Clin Oncol 2001;19:697-704.
29. Wössmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003;82:160-165.